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Abstract
Background: Important diagnostic and clinical aspects of moderately reduced von 
Willebrand factor (VWF) levels are still unknown. There is no clear evidence which 
cutoff value (0.50 vs 0.60 IU/ml) should be used to diagnose “low VWF.” Also, the 
incidence of bleeding after the diagnosis has been made, and risk factors for bleeding 
are unknown yet.
Objectives: To investigate the incidence of postsurgical bleeding, postpartum hemor-
rhage (PPH), and traumatic and spontaneous bleeding after low VWF diagnosis, and 
to develop a risk score to predict future bleeding.
Methods: We performed a cohort study in patients with historically lowest VWF lev-
els of 0.31 to 0.60 IU/ml. Clinical data of patients were retrospectively collected.
Results: We included 439 patients with low VWF. During a follow-up of 6.3 ± 3.7 
years, 259 surgical procedures, 81 deliveries, and 109 spontaneous and traumatic 
bleeding episodes were reported. The incidence of postsurgical bleeding was 2.7%, 
whereas 10% of deliveries was complicated by PPH. Overall, 65 patients (14.8%) had 
bleeding requiring treatment, which was not different between patients with histori-
cally lowest VWF levels of 0.31–0.50 and 0.51–0.60 IU/ml (p = .154). Age <18 years, 
abnormal bleeding score at diagnosis, and being referred for bleeding symptoms at 
the time of diagnosis were independent risk factors for bleeding during follow-up, and 
therefore included in the risk score.
Conclusions: The cutoff value of low VWF diagnosis should be set at 0.60 IU/ml. 
Furthermore, a risk score is developed to identify individuals with a high risk for 
bleeding after low VWF diagnosis.
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1  |  INTRODUC TION
Von Willebrand factor (VWF) is a multimeric glycoprotein with 
an important role in primary hemostasis by binding platelets to 
subendothelial collagen at sites of vascular damage and by initi-
ating platelet aggregation to form a platelet plug.1–3 In addition, 
VWF is a carrier protein for coagulation factor VIII (FVIII), pre-
venting its proteolytic degradation and thereby prolonging FVIII 
half-life.1,3
A deficiency or an abnormal function of VWF, which is prevalent 
in approximately 1% of the general population, may lead to bleeding 
symptoms.4,5 Individuals with VWF levels below 0.30 IU/ml are di-
agnosed with von Willebrand disease (VWD).1 Most patients with 
VWD have a significant bleeding phenotype and a VWF mutation, 
especially those with type 2 and type 3 VWD.1 A milder decrease 
of VWF levels (i.e., levels of 0.31-0.50 IU/ml) does not always lead 
to bleeding symptoms because only a small fraction of individuals 
with such VWF levels have a significant bleeding phenotype.2,5–8 As 
a consequence, it has been suggested that reduced VWF levels in 
the range of 0.31 to 0.50 IU/ml is a risk factor for bleeding and not 
a disease.9,10 According to current guidelines individuals with VWF 
levels of 0.31 to 0.50 IU/ml and a significant bleeding phenotype are 
classified as “low VWF.”6–8
Although several large studies have recently provided valu-
able insights on the pathophysiology, diagnosis, bleeding pheno-
type, and treatment outcomes of VWD patients, these aspects 
remain poorly understood in individuals with low VWF.11–17 Most 
importantly, there is no clear evidence which cutoff value should 
be used to diagnose low VWF.18 The most recommended cutoff 
value is 0.50 IU/ml,8 although VWF levels in the range of 0.51 to 
0.60 IU/ml may also contribute to bleeding.19 Moreover, 0.60 IU/
ml is in some laboratories the lower limit of normal and therefore 
used as cutoff value to diagnose low VWF. No studies have been 
performed yet to determine the difference in bleeding pheno-
type of individuals with VWF levels of 0.31 to 0.50 IU/ml and 
0.51 to 0.60 IU/ml.18 Second, the incidence of postsurgical bleed-
ing, postpartum hemorrhage (PPH) and traumatic or spontaneous 
bleeding after diagnosis of low VWF are not known yet. It is also 
not known which factors are associated with the risk of these 
bleeding. Last, it is hard to predict which individuals with low 
VWF are at increased risk for bleeding and which individuals will 
almost never have bleeding episodes after they are diagnosed 
with low VWF.
Therefore, we investigated whether there is a difference in the 
bleeding phenotype of individuals with historically lowest VWF lev-
els of 0.31 to 0.50 IU/ml and 0.51 to 0.60 IU/ml. Second, we inves-
tigated the incidence of postsurgical bleeding, PPH, and traumatic 
and spontaneous bleeding in individuals with low VWF after their 
initial diagnosis. We also studied which factors are associated with 
the risk of such bleeding. Last, we combined these risk factors to 
develop a risk score to predict which individuals with low VWF are 
at increased risk for future bleeding.
2  |  METHODS
2.1  |  Setting and participants
We performed a retrospective cohort study from January 2007 
to November 2019 at the Erasmus University Medical Center, 
Rotterdam, the Netherlands. All patients evaluated for the pres-
ence of a bleeding disorder at the outpatient department, with 
VWF antigen (VWF:Ag) and/or VWF activity (VWF:Act) and/or 
VWF collagen binding (VWF:CB) levels between 0.31 and 0.60 IU/
ml measured at least at one time point between January 2007 and 
November 2019, were included. Patients with VWF:Ag and/or 
VWF:Act and/or VWF:CB ≤0.30 IU/ml ever measured, those with 
acquired VWD, and patients with concomitant bleeding disorder 
were excluded.
2.2  |  Assessment methods
At inclusion, the bleeding phenotype of all individuals with VWF lev-
els between 0.31 and 0.60 IU/ml was obtained by a consultant he-
matologist specializing in bleeding disorders. These data were used 
to calculate the ISTH-Bleeding Assessment Tool (ISTH-BAT).20 In 
patients that were included before the ISTH-BAT was published, we 
have retrospectively calculated the ISTH-BAT based on the infor-
mation reported in the electronic patient files. An abnormal ISTH-
BAT is defined as a score of ≥3 in children, ≥4 in males, and ≥6 in 
females.20,21
Retrospective follow-up started at the moment of low VWF di-
agnosis and continued until November 2019. For each individual, we 
collected data on baseline characteristics, reason for consultation, 
family history of bleeding disorders, ISTH-BAT at diagnosis, and 
laboratory measurements. Furthermore, follow-up data on surgical 
procedures, pregnancies, deliveries, and incidence of spontaneous 
and traumatic bleeding were collected from electronic patient files.
Essentials
• There is no clear evidence which cut-off value (0.50 vs 
0.60 IU/ml) should be used to diagnose “low VWF.”
• We performed a cohort study with a mean follow-up of 
6.3 ± 3.7 years in patients with historically lowest VWF 
levels of 0.31–0.60 IU/ml.
• No difference was found in the bleeding phenotype of 
patients with historically lowest VWF levels of 0.31–
0.50 and 0.51–0.60 IU/ml.
• A risk score is developed to identify individuals with a 
high, intermediate and low risk for bleeding after low 
VWF diagnosis.
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2.3  |  Laboratory measurements
Plasma levels of VWF:Ag, VWF:Act, VWF:CB, and FVIII activity 
(FVIII:C) were determined at the hemostasis laboratory of the 
Erasmus University Medical Center. Previous studies provide de-
tailed information on blood sampling procedures and laboratory 
measurements.16,22 Briefly, for VWF:Ag and VWF:CB, in-house 
enzyme-linked immunosorbent essays were used. Detection of 
VWF:Ag was performed using polyclonal rabbit anti-human VWF 
antibodies and horseradish peroxidase conjugated anti-human 
VWF antibodies (DakoCytomation, Glostrup, Denmark). For 
VWF:CB, collagen type 1 (Sigma-Aldrich, St Louis, MO) was used 
for capturing and horseradish peroxidase–conjugated anti-human 
VWF antibodies (DakoCytomation) for detection. Before 2012, 
VWF:Act was measured with the VWF:Ab assay (HemosIL VWF 
activity; Instrumentation Laboratory BV, Breda, the Netherlands), 
which used monoclonal antibodies against the GP1ba binding site 
of VWF, reflecting the binding activity of VWF to GP1ba.22,23 
From 2012 on, VWF:Act was measured with the VWF:GPIbM 
Innovance assay from Siemens on a Sysmex CS-5100. FVIII:C was 
measured using a one-stage clotting assay (TriniCLOT; bioMé-
rieux, Marcy l’Etoile, France) on the Sysmex CS-5100 (Siemens). 
Multimeric patterns were evaluated with the use of low-resolution 
0.9% agarose gel electrophoresis (Bio-Rad Laboratories) followed 
by capillary Western blotting. VWF multimers were classified as 
either absent, abnormal, or normal based on comparison with 
commercial reference plasma (normal reference plasma; Precision 
Biologic). Additional coagulation tests were measured with vali-
dated standard diagnostic assays.
2.4  |  Definitions
Surgical procedures were defined as medical interventions that in-
vade the body by cutting or puncturing the skin and/or by insert-
ing instruments into the body, such as surgery, dental procedures, 
or invasive examinations.23 Because there is a large variability in the 
bleeding risk of such interventions, we have classified the bleeding 
risk of each intervention based on previous literature.24 Furthermore, 
major postsurgical bleeding was defined as bleeding requiring re-
surgery or blood transfusion, whereas minor postsurgical bleeding 
was defined as bleeding requiring additional tranexamic acid (TXA), 
desmopressin or VWF concentrates, or bleeding for which patients 
had to stay longer at the hospital or had to visit the outpatient depart-
ment or emergency room of the Erasmus University Medical Center. 
PPH was defined as blood loss ≥500 mL within 24 hours’ postpartum 
or bleeding for which curettage, additional TXA, desmopressin, or 
VWF concentrate was necessary. Severe PPH was defined as blood 
loss ≥1000 mL within 24 hours’ postpartum.25 Secondary PPH was 
defined as blood loss occurring between 24 hours’ and 6 weeks’ 
postpartum.26 Peripartum blood loss was estimated by the obste-
trician-gynecologist who supervised the delivery, as is routinely 
done in the Netherlands. Trauma was defined as an event for which 
patients contacted the outpatient department or emergency room 
of the Erasmus University Medical Center. Spontaneous or trau-
matic bleeding during follow-up was defined as bleeding for which 
patients contacted the outpatient department or ER. Last, bleeding 
requiring treatment was defined as bleeding treated with tranexamic 
acid (TXA), desmopressin, VWF containing concentrates, blood 
transfusion, (re)surgery, cauterization in case of epistaxis, suturing 
of wounds, hormonal therapy, or a hormone containing intrauterine 
device in case of menorrhagia and curettage in case of PPH.
2.5  |  Statistical analyses
Categorical variables are presented as frequencies and percentages 
(n, %), whereas continuous variables are presented as mean (± stand-
ard deviation). Normality of data was assessed with histograms. 
Missing data were not replaced.
Parametric tests were used in case of analyzing more than 30 
individuals or normal distributed data. An independent t-test or 
one-way analysis of variance was used to compare continuous vari-
ables between different groups. Differences in categorical data 
among different subgroups were analyzed using a chi-squared test. 
Kaplan-Meier analysis with log-rank test was performed to deter-
mine whether there was a difference in time to bleeding requiring 
treatment between categorical variables. Cox regression analysis 
was used to determine whether there was a difference in time to 
bleeding requiring treatment between continuous variables. For 
the association between hemostatic laboratory measurements and 
risk of bleeding requiring treatment, we have used the historically 
lowest levels as independent variables. To identify independent risk 
factors for bleeding requiring treatment, we performed a cox regres-
sion analysis with forward (Wald) method in which we included all 
variables that were significantly associated with bleeding requiring 
treatment in univariate analysis. Outcomes of Cox regression anal-
ysis are presented as hazard ratio followed by the 95% confidence 
interval (CI) and p value. Statistical analyses were performed using 
SPSS Statistics version 25 (IBM Corp.). A p value below .05 was de-
fined as statistically significant.
3  |  RESULTS
In our outpatient hemophilia treatment center, we identified 476 
patients referred because of a personal bleeding diathesis, family 
history of VWD or low VWF, or incidentally found laboratory ab-
normalities, in whom laboratory assessment revealed VWF levels 
between 0.31 and 0.60 IU/ml from 2007 to November 2019. A con-
comitant bleeding disorder was present in 37 (7.8%) individuals, of 
whom 12 were carriers of hemophilia A, five had hemophilia A or B, 
10 had a platelet function disorder, five had thrombocytopenia, and 
five had a rare bleeding disorder. These individuals were excluded 
from this study, and therefore we included 439 patients of whom 
269 patients with historically lowest VWF levels between 0.31 and 
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0.50 IU/ml and 170 patients with historically lowest levels between 
0.51 and 0.60 IU/ml (Table 1).
The reason for referral was a personal bleeding diathesis in 288 
(65.6%) patients, a positive family history of VWD or low VWF in 
138 (31.4%) patients and incidentally found laboratory abnormali-
ties in 13 (3.0%) patients (Table 1). Mean age at diagnosis and inclu-
sion in the study was 28.8 ± 17.7 years, and was lower in patients 
with historically lowest levels of 0.31 to 0.50 IU/ml (26.7 ± 17.3) 
compared with those with 0.51 to 0.60 IU/ml (32.1 ± 17.8, p = .002). 
Most patients were female (74.3%) and had blood group O (76.4%) 
(Table 1). The mean follow-up period after diagnosis was 6.3 ± 3.7 
years. Figure 1 gives an overview of the number of patients with sur-
gical procedures, deliveries, and traumatic and spontaneous bleed-
ing during follow-up.
3.1  |  Bleeding score at diagnosis
The mean ISTH-BAT bleeding score at diagnosis was 3.8 ± 3.0, and 
was abnormal in 163 individuals (37.1%). Individuals referred for a 
personal bleeding diathesis presented with a higher bleeding score 
at diagnosis (4.6 ± 2.8) compared with those referred because of a 
family history of VWD or low VWF (2.2 ± 2.7, p < .001). Additionally, 
the number of individuals with an abnormal bleeding score was 138 
(47.9%) in those referred for a personal bleeding diathesis, whereas 
it was only 21 (15.2%) in those referred for a family history of VWD 
or low VWF, and four (30.8%) in those referred because of an inci-
dentally found laboratory abnormality (p < .001). After adjustment 
for age and sex, individuals referred for a personal bleeding diath-
esis had a five times higher chance of presenting with an abnormal 
bleeding score compared with patients referred for family history of 
VWD or low VWF: odds ratio = 5.0 (3.0-8.4). The bleeding score was 
similar between patients with historically lowest VWF levels 0.31 to 
0.50 IU/ml and 0.51 to 0.60 IU/ml, respectively 3.7 ± 3.0 vs 4.0 ± 2.9 
(p = .209) (Table 1). Likewise, the number of individuals with an ab-
normal bleeding score was similar between patients with historically 
lowest VWF levels 0.31 to 0.50 IU/ml and 0.51 to 0.60 IU/ml, re-
spectively 96 (35.7%) vs 67 (39.4%) (p = .431) (Table 1).
3.2  |  Surgical procedures during follow-up
During the follow-up period of 6.3 ±3.7 (mean ± standard deviation) 
years, 259 surgical procedures were performed in 146 individuals. 
Of these procedures, 233 (90.0%) were preceded by prophylactic 
treatment, which was desmopressin and TXA in 105 procedures 
Historically Lowest VWF Levels
Total





Age at diagnosis (years) 26.7 ± 17.3 32.1 ± 17.8 28.8 ± 17.7 0.002
Female 193 (71.7%) 133 (78.2%) 326 (74.3%) 0.130
Blood group O 178 (77.4%) 103 (74.6%) 281 (76.4%) 0.547
BMI (kg/m2) 23.2 ± 5.3 23.5 ± 5.2 23.3 ± 5.2 0.662
Reason for referral
Bleeding diathesis 172 (63.9%) 116 (68.2%) 288 (65.6%) 0.473
Family history 90 (33.5%) 48 (28.2%) 138 (31.4%)
Laboratory abnormalitya  7 (2.6%) 6 (3.5%) 13 (3.0%)
Historically lowest levels
VWF:Ag (IU/ml) 0.51 ± 0.12 0.62 ± 0.11 0.55 ± 0.13 <0.001
VWF:Act (IU/ml) 0.47 ± 0.09 0.62 ± 0.08 0.53 ± 0.11 <0.001
VWF:CB (IU/ml) 0.55 ± 0.18 0.69 ± 0.16 0.60 ± 0.18 <0.001
FVIII:C (IU/ml) 0.78 ± 0.21 0.90 ± 0.21 0.83 ± 0.22 <0.001
PFA epi (seconds) 185 ± 48 168 ± 43 178 ± 47 0.001
PFA ADP (seconds) 151 ± 44 138 ± 31 147 ± 40 0.004
Bleeding score at diagnosis 3.7 ± 3.0 4.0 ± 2.9 3.8 ± 3.0 0.209
Abnormal bleeding scoreb  96 (35.7%) 67 (39.4%) 163 (37.1%) 0.431
Follow-up (years) 6.6 ± 3.7 5.9 ± 3.7 6.3 ± 3.7 0.068
Note: Data presented as mean ± standard deviation or number (%), unless otherwise specified.
Abbreviations: Act, activity; ADP, adenosine diphosphate; Ag, antigen; BMI, body mass index; CB, 
collagen binding; epi, epinephrine; FVIII:C, factor VIII activity; PFA, platelet function assay; VWF, 
von Willebrand factor.
aIncidentally found for instance with PFA screening before surgery. 
bAbnormal ISTH-BAT is defined as ≥3 in children, ≥4 in males, and ≥6 in females. 
TA B L E  1  Baseline characteristics
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(45.1%), desmopressin alone in 47 procedures (20.2%), VWF con-
taining concentrates with or without TXA in 62 procedures (26.6%), 
and TXA alone in 15 procedures (6.4%). Major bleeding, defined as 
bleeding requiring resurgery or blood transfusion, occurred in four 
procedures (1.5%), whereas minor bleeding occurred in three pro-
cedures (1.2%). Table 2 shows detailed information of the seven 
patients with a postsurgical bleeding. Two of the four individuals 
with a major bleeding had important comorbidities and an American 
Society of Anesthesiologists Physical Status score of 4. Both pa-
tients underwent major surgery. Moreover, one of them restarted 
clopidogrel after surgery and before the occurrence of bleeding. 
Furthermore, a young child with persistent bleeding within 2 hours 
after adenotonsillectomy needed resurgery because of a clear ana-
tomical bleeding focus, which was effectively treated with thermal 
coagulation. The last patient with a major bleeding, which occurred 8 
days after facial nerve reconstruction, did not have a local cause for 
bleeding. Likewise, no cause for bleeding was identified in the three 
patients with minor bleeding.
Last, in 233 procedures that were preceded by prophylactic 
treatment, none of the patients developed side effects of hemo-
static treatment, such as venous or arterial thrombosis.
3.3  |  Postpartum hemorrhage during follow-up
Fifty-six women had 81 deliveries during follow-up. In 16 deliveries 
(19.8%) prophylactic treatment was given at delivery. Overall, eight 
deliveries (9.9%) were complicated by a PPH, of which one occurred 
despite prophylactic treatment (1/16: 6.3%) and seven in deliveries 
in which no prophylactic treatment was given (7/65: 10.8%) (p = .587, 
Figure 1). The woman with PPH despite prophylactic treatment, re-
ceived platelet transfusion and TXA as prophylaxis, because she had 
experienced PPH in a prior delivery despite normalization of VWF 
levels in the third trimester. Table 3 shows the characteristics of 
women with PPH. All women with PPH had normalized VWF levels 
in the third trimester (i.e., VWF:Act and VWF:Ag >1.00 IU/ml). Four 
women had primary PPH, three had secondary PPH, and one had 
both primary and secondary PPH. Interestingly, all women with PPH 
of whom obstetric risk factors during delivery could be retrieved 
from the patient files (n = 7), had a retained placenta. Furthermore, 
five of eight women (62.5%) who had a PPH during follow-up had 
a history of PPH before diagnosis of low VWF, whereas in women 
who did not have PPH during follow-up only 12 of 48 (25.0%) had a 
history of PPH before diagnosis (p = 0.047).
3.4  |  Spontaneous and traumatic bleeding during 
follow-up
During follow-up, 109 spontaneous and traumatic bleeding epi-
sodes occurred in 71 individuals. Treatment such as hemostatic 
treatment, blood transfusion, cauterization for epistaxis, suturing 
of wounds, hormonal therapy, or intrauterine device for menor-
rhagia was required in 79 spontaneous and traumatic bleeding 
events, which occurred in 53 patients. Thirty-seven patients had a 
spontaneous bleeding for which they required treatment, whereas 
13 patients had traumatic bleeding and three had both spontane-
ous and traumatic bleeding during follow-up. The type of bleeding 
for which most patients needed treatment during follow-up was 
menorrhagia (Figure 2). Twenty-five women received treatment 
for menorrhagia, which were hormonal therapy alone, TXA alone, 
hormonal therapy and TXA combined, desmopressin, or blood 
transfusion in one woman. Nine patients received treatment be-
cause of epistaxis, five because of gastrointestinal bleeding and 
F I G U R E  1  Overview of surgical procedures, bleeding, and child deliveries during follow-up. PPH, postpartum hemorrhage. 1Bleeding 
requiring resurgery or blood transfusion
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two because of hematuria (Figure 2). Hematoma, bleeding from 
wounds, and central nervous system bleeding requiring treatment 
each occurred in a single patient (Figure 2). Spontaneous and trau-
matic bleeding requiring treatment was observed in 43 (14.9%) 
patients originally referred for bleeding, nine (6.5%) patients origi-
nally referred because of family history of VWD or low VWD and 
two (15.4%) patients referred because of an incidentally found lab-
oratory abnormality (p = .044). There was no significant difference 
in the number of patients with spontaneous or traumatic bleeding 
during follow-up between patients with historically lowest VWF 
levels 0.31 to 0.50 IU/ml and 0.51 to 0.60 IU/ml, respectively, 38 
patients (14.1%) vs 16 patients (9.4%), p = .143.
3.5  |  Risk factors for bleeding requiring treatment 
during follow-up
Overall, only 65 of 439 patients (14.8%) had a bleeding episode 
(surgical, PPH, and spontaneous and traumatic bleeding combined) 
requiring treatment during the mean follow-up of 6.3 ± 3.7 years. 
This resulted in an incidence of bleeding requiring treatment of 0.5 
±1.9 per patient per decade. There was no difference in incidence of 
bleeding requiring treatment between patients with historically low-
est VWF levels 0.31 to 0.50 IU/ml and 0.51 to 0.60 IU/ml (p = .154, 
Figure 3A). Also, no difference in risk of bleeding requiring treat-
ment was observed between men and women (p = .752, Figure 3B). 
Although women had more often sex-specific bleeding such as 
menorrhagia and PPH during follow-up, men had more often trau-
matic bleeding requiring treatment compared with women, respec-
tively, 8.0% of men vs 2.1% of women (p = .008). Remarkably, blood 
group non-O was associated with a higher risk of bleeding requiring 
treatment during follow-up (p = .044, Figure 3C), whereas patients 
younger than 17 years at diagnosis also had a higher risk of bleed-
ing requiring treatment during follow-up compared to patients age 
40 years or older (i.e., quartile 1 vs quartile 4, p = .041, Figure 3D). 
Furthermore, bleeding score at diagnosis (hazard ratio [HR] = 1.08 
increase per point; 95% CI, 1.01-1.17; p = .032) and an abnormal 
bleeding score at diagnosis were also associated with a higher risk of 
bleeding requiring treatment during follow-up (p = .001, Figure 3E). 
Last, patients referred because of a personal bleeding diathesis had 
a higher risk of bleeding requiring treatment during follow-up com-
pared with patients referred because of family history (p = .001, 
Figure 3F).
3.6  |  Hemostatic laboratory measurements and 
risk of bleeding requiring treatment
Of all hemostatic laboratory measurements, we found that higher 
VWF:CB/VWF:Ag ratio (continuous variable) was associated with 
a lower risk of bleeding requiring treatment during follow-up: 
HR = 0.27 (95% CI, 0.10-0.76; p = .013; Table S1). There was also 
a clear difference in risk of bleeding requiring treatment between 
patients VWB:CB/VWF:Ag in the first quartile compared with those 
in the fourth quartile (p = .039).
3.7  |  Independent risk factors for bleeding 
requiring treatment
To identify independent risk factors for bleeding requiring treatment 
in individuals with low VWF, we performed a Cox regression analysis 
with forward (Wald) method in which we included blood group, age 
at diagnosis, bleeding score at diagnosis, and reason for referral as 
independent variables. We found that referral for a personal bleed-
ing diathesis, younger age at diagnosis, and an abnormal bleeding 
score at diagnosis were strong independent risk factors for bleeding 
requiring treatment during follow-up, respectively HR = 2.32 (95% 
CI, 1.16-4.63; p = .017), HR = 1.18 (95% CI, 1.01-1.38; p = .036), and 
HR = 1.77 (95% CI, 1.04-3.01; p = .036).
3.8  |  Risk score to identify individuals with 
increased risk for bleeding requiring treatment
We combined the risk factors described previously to develop a 
risk score to identify low VWF patients with an increased risk for 
bleeding requiring treatment after diagnosis (Table 4). Individuals 
with a total risk score of 0 or 1 are classified as low risk, those 
with a total score of 2 are classified as intermediate risk, and those 
with a total risk score 3 to 5 are classified as high risk. The risk 
score performed excellently to distinguish in risk for bleeding re-
quiring treatment between low-, intermediate-, and high-risk pa-
tients with low VWF (p < .001, Figure 4). The number of patients 
with bleeding requiring treatment was 8/126 (6.3%) in individu-
als with low-risk, 18/143 (12.6%) in intermediate-risk, and 39/170 
(22.9%) in high-risk patients (p < .001, Figure 4A). Likewise, the 
F I G U R E  2  Number of patients with bleeding requiring 
treatment during follow-up. CNS, central nervous system; PPH, 
postpartum hemorrhage
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incidence of bleeding requiring treatment per patient per decade 
was 0.22 ± 1.08 in low-risk, 0.28 ± 1.25 in intermediate-risk, and 
0.87 ± 2.61 in high-risk individuals (p = .004, Figure 4B).
4  |  DISCUSSION
In this large retrospective cohort study in patients with low VWF, we 
found no difference in the bleeding phenotype of patients with his-
torically lowest VWF levels between 0.31 to 0.50 IU/ml and 0.51 to 
0.60 IU/ml. Second, we observed that prophylactic treatment during 
surgical procedures were effective in preventing bleeding and safe, 
as evidenced by a low rate of postsurgical bleeding and absence of 
side effects. Furthermore, 15% of patients required treatment for 
bleeding after diagnosis of low VWF, during an average follow-up 
of 6 years. Risk factors that were independently associated with 
bleeding requiring treatment during follow-up were younger age at 
F I G U R E  3  Risk factors for bleeding requiring treatment during follow-up. Results are presented as Kaplan-Meier curves. 1Percentage of 
patients with a bleeding requiring treatment during follow-up. BS, bleeding score; VWF, von Willebrand factor
TA B L E  4  Risk score to identify the bleeding-requiring-treatment 
risk of patients with low VWF
Risk Score
Age <18 years at diagnosis 1
Abnormal bleeding score at diagnosis 2
Referred for personal bleeding diathesis 2
Note: Total risk score of 0-1: low risk. Total risk score of 2: intermediate 
risk. Total risk score of 3-5: high risk.
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diagnosis, abnormal bleeding score at diagnosis and referral for per-
sonal bleeding diathesis. Based on these factors, we developed a risk 
score to identify low VWF patients with high, intermediate, and low 
risk for future bleeding requiring treatment.
The cutoff value for diagnosing low VWF is still debated in re-
cent literature.19 In laboratories with 0.60 IU/ml as the lower limit 
of normal VWF levels, our results support a cutoff value of 0.60 IU/
ml for low VWF diagnosis, and suggest that there should be no dis-
tinction in the management of individuals with historically lowest 
VWF levels 0.31 to 0.50 IU/ml and 0.51 to 0.60 IU/ml because the 
bleeding phenotype of both groups is similar. Correctly defining in-
dividuals with low VWF is essential because diagnosis or rejection of 
low VWF diagnosis has not only major consequences for the index 
patient in case of future interventions, pregnancies, deliveries, and 
management of future bleeding, but also for their family members 
because they are often analyzed when an index patient is identified. 
Accordingly, in the LoVIC study, no difference was found in bleeding 
score between individuals with VWF levels 0.30 to 0.39 IU/ml com-
pared with those with VWF levels 0.40 to 0.50 IU/ml.6,8 Together 
with the results of our current study, this suggests that there is no 
critical VWF level in respect to bleeding risk, at least not in the range 
of 0.31 to 0.60 IU/ml. In line, from all VWF laboratory parameters, 
only historically lowest VWF:CB/VWF:Ag ratio was associated with 
the bleeding risk during follow-up in the current study. This is prob-
ably explained by the fact that lower VWF:CB is associated with a 
reduction of high molecular weight VWF multimers, which may lead 
to a lower hemostatic potential.27,28
Fifteen percent of all individuals with low VWF experienced a 
bleeding episode requiring treatment during an average of 6 years 
after they were diagnosed with low VWF. Therefore, we developed 
a risk score to distinguish individuals with the highest risk for fu-
ture bleeding from those with an intermediate risk and low risk. In 
adults with VWD, it was previously shown that a bleeding score 
above 10 is predictive for future bleeding.29 In our current study we 
found that an abnormal bleeding score at diagnosis combined with 
referral for bleeding and age younger than 18 years at diagnosis, 
were strongly associated with the risk for future bleeding. A benefit 
of this risk score is that it includes all individuals with historically 
lowest VWF levels between 0.31 and 0.60 IU/ml, irrespective of 
their clinical features and reason for referral. For instance, individ-
uals with levels of 0.31 to 0.60 IU/ml without a significant bleeding 
phenotype are in this risk score classified as individuals with low 
risk for bleeding. Likewise, those with levels 0.31 to 0.60 IU/ml and 
a significant bleeding phenotype are classified as intermediate or 
high risk based on their risk score. Nevertheless, it should be noted 
that in all included patients, current guidelines for prophylactic 
treatment during interventions and pregnancies were followed, and 
therefore the purpose of this risk score is not to determine the need 
for prophylactic treatment, but to make physicians and patients 
aware of the severity of bleeding risk in an individual. Future studies 
are needed to validate this risk score in other cohorts of individuals 
with low VWF.
The incidence of postsurgical bleeding was 2.7% after individ-
uals were diagnosed with low VWF and 90% of procedures were 
preceded by prophylactic treatment. It is hard to compare this 
percentage with the incidence rate of postsurgical bleeding in the 
general population, because the bleeding rate highly depends on 
the type of surgery. In the general population, the incidence of 
postsurgical bleeding is estimated to be about 2% to 5%, depen-
dent on the type of surgery.30–32 Therefore, it seems like postsur-
gical bleeding does not occur more frequent in individuals with low 
VWF after their diagnosis. This can be explained by the fact that 
individuals with low VWF are closely monitored during surgical 
procedures, and prophylactic treatment is administered if deemed 
necessary based on VWF levels before surgical procedure, type of 
surgery, and concomitant risk factors for bleeding. Furthermore, in 
the general population it is known that 75% to 90% of intraopera-
tive and early postoperative bleeding are due to technical, surgical 
factors.33 Therefore, this should also not be neglected as potential 
risk factor for postsurgical bleeding in individuals with low VWF. 
Indeed, three of the four major postsurgical bleeding events in our 
cohort were associated with comorbidities, high-risk surgery, and 
surgical factors. Last, we found that prophylactic treatment for 
surgery was not complicated by side effects such as thrombosis, 
suggesting that prophylactic treatment based on current guidelines 
is safe in these individuals.
F I G U R E  4  The risk score performs excellent in identifying individuals with low VWF with an increased risk for bleeding requiring 
treatment. (A) Kaplan-Meier curve of 1percentage of patients with a bleeding requiring treatment during follow-up. (B) Bleeding requiring 
treatment rate per patient per decade. VWF, von Willebrand factor
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The incidence of PPH was 10% and the incidence of severe 
PPH was 6% during follow-up, despite management of pregnant 
women according to current guidelines and giving prophylactic 
treatment if needed. Both the incidence of PPH and severe PPH 
seemed to be higher in our cohort of women with low VWF com-
pared with the general population, in which the incidence of PPH 
is about 1% to 4.5%.25,34,35 Incidence of PPH during follow-up was 
lower in women with low VWF compared with those reported in a 
retrospective cohort study in women with VWD, who had a PPH 
incidence of 34%.36 However, the incidence of severe PPH was 
comparable between women with low VWF and VWD, which was 
in both studies 8%.36–38 Likewise, in parous women, the percent-
age of self-reported PPH during a lifetime was 63.5% in low VWF 
patients in the LoVIC study, whereas this number was 51% in VWD 
patients in the WiN study.39,40 This suggests that the self-reported 
incidence of PPH during a lifetime is comparable between women 
with low VWF and VWD.39,40 Furthermore, in the current study, 
we found that prior PPH was a risk factor for future PPH in women 
with low VWF. Also, in seven of eight women with PPH, we were 
able to obtain detailed information about obstetric risk factors, 
and found that all these women had a retained placenta, whereas 
in the general population, only 20% of women with PPH have a 
retained placenta.35 Both prior PPH and retained placenta were 
in the general population also identified as important risk factors 
for future PPH.35 Furthermore, a retained placenta is in the gen-
eral population only present in 1% to 3% of all deliveries, whereas 
in our cohort the incidence of retained placenta was 9%.34,35,41 
Future studies should systematically investigate the incidence of 
PPH and its association with obstetric risk factors in women with 
low VWF.
The most important limitation of this study is the retrospective 
design. However, being aware of this limitation, we mainly focused 
on clinically relevant bleeding for which patients needed treatment 
and contacted our center. Because current national guidelines in 
the Netherlands recommend the treatment of inherited bleed-
ing disorders to take place at a Hemophilia Treatment Center, we 
consider the data on bleeding requiring treatment to be reliable. 
Moreover, prospective studies on this subject are probably not 
feasible, because of the low incidence of bleeding requiring treat-
ment one may either need thousands of patients or a very long 
follow-up to include enough “events” to have sufficient power to 
draw conclusions from such a study. In our current study, we in-
cluded 439 patients and followed them up for an average of 6.3 
years, resulting in 2766 patient-years of follow-up. During this fol-
low-up period, 94 events (i.e., bleeding requiring treatment) oc-
curred, which was sufficient to answer the predefined primary and 
secondary research questions. We do acknowledge that the risk 
of bleeding episodes that do not require treatment cannot be re-
liably obtained from a retrospective study because most of those 
bleeding episodes are not communicated by patients to the hos-
pital. Therefore, numbers on bleeding that did not require treat-
ment may be underestimated and prospective studies are needed 
to investigate those bleeding. Furthermore, we acknowledge that 
our study population of low VWF patients referred to our tertiary 
center, is a selected group and therefore not comparable with indi-
viduals with low VWF in the general population, most of whom do 
not have an increased bleeding phenotype.
To conclude, the results of this study suggest that in laboratories 
with 0.60 IU/ml as the lower limit of normal VWF levels there should 
be no distinction in the management of individuals with historically 
lowest VWF levels of 0.31 to 0.50 IU/ml and 0.51 to 0.60 IU/ml. 
Therefore, the cutoff value of diagnosing low VWF should be set at 
0.60 IU/ml in these laboratories. Furthermore, the risk score devel-
oped in the current study may assist in the management of individ-
uals with low VWF, to identify patients with high, intermediate, and 
low risk for future bleeding.
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